West Pharmaceutical Servs Analyst Ratings
West Pharmaceutical Servs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/27/2023 | 19.99% | Stephens & Co. | $420 → $390 | Maintains | Overweight |
| 08/30/2023 | 35.37% | Keybanc | $415 → $440 | Maintains | Overweight |
| 08/21/2023 | 27.68% | Keybanc | $385 → $415 | Maintains | Overweight |
| 07/28/2023 | 18.45% | Keybanc | $375 → $385 | Maintains | Overweight |
| 07/17/2023 | 29.22% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
| 06/16/2023 | 24.61% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
| 04/11/2023 | 23.07% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
| 02/17/2023 | 15.38% | Keybanc | $315 → $375 | Maintains | Overweight |
| 12/14/2022 | -23.08% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
| 12/02/2022 | -3.08% | Keybanc | $350 → $315 | Maintains | Overweight |
| 11/30/2022 | -23.08% | UBS | → $250 | Initiates Coverage On | → Neutral |
| 10/28/2022 | -23.08% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
| 10/28/2022 | 7.68% | Keybanc | $400 → $350 | Maintains | Overweight |
| 07/29/2022 | 6.15% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
| 04/29/2022 | 26.14% | B of A Securities | $475 → $410 | Maintains | Buy |
| 04/29/2022 | 23.07% | Keybanc | $475 → $400 | Maintains | Overweight |
| 09/15/2021 | 58.45% | B of A Securities | $450 → $515 | Maintains | Buy |
| 07/30/2021 | 23.07% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
| 07/30/2021 | 46.14% | Keybanc | $350 → $475 | Maintains | Overweight |
| 04/30/2021 | 4.61% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
| 02/19/2021 | -3.08% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
| 11/10/2020 | 7.68% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
| 10/14/2020 | -7.7% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
| 04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月27日 | 19.99% | 斯蒂芬斯公司 | $420→$390 | 維護 | 超重 |
| 2023年08月30日 | 35.37% | KeyBanc | $415→$440 | 維護 | 超重 |
| 2023年08月21日 | 27.68% | KeyBanc | $385→$415 | 維護 | 超重 |
| 07/28/2023 | 18.45% | KeyBanc | $375→$385 | 維護 | 超重 |
| 07/17/2023 | 29.22% | 斯蒂芬斯公司 | $400→$420 | 維護 | 超重 |
| 06/16/2023 | 24.61% | B of A證券 | $390→$405 | 升級 | 中性→購買 |
| 04/11/2023 | 23.07% | 斯蒂芬斯公司 | $330→$400 | 升級 | 等重→超重 |
| 02/17/2023 | 15.38% | KeyBanc | $315→$375 | 維護 | 超重 |
| 2022年12月14日 | -23.08% | 德意志銀行 | →$250 | 開始承保 | →保留 |
| 12/02/2022 | -3.08% | KeyBanc | $350→$315 | 維護 | 超重 |
| 2022年11月30日 | -23.08% | 瑞銀集團 | →$250 | 開始承保 | →中性 |
| 10/28/2022 | -23.08% | B of A證券 | $385→$250 | 評級下調 | 購買→中性 |
| 10/28/2022 | 7.68% | KeyBanc | $400→$350 | 維護 | 超重 |
| 07/29/2022 | 6.15% | 斯蒂芬斯公司 | $330→$345 | 維護 | 等重 |
| 04/29/2022 | 26.14% | B of A證券 | $475→$410 | 維護 | 買 |
| 04/29/2022 | 23.07% | KeyBanc | $475→$400 | 維護 | 超重 |
| 2021/09/15 | 58.45% | B of A證券 | $450→$515 | 維護 | 買 |
| 07/30/2021 | 23.07% | 斯蒂芬斯公司 | $360→$400 | 維護 | 等重 |
| 07/30/2021 | 46.14% | KeyBanc | $350→$475 | 維護 | 超重 |
| 04/30/2021 | 4.61% | 斯蒂芬斯公司 | $315→$340 | 維護 | 等重 |
| 02/19/2021 | -3.08% | 斯蒂芬斯公司 | $300→$315 | 維護 | 等重 |
| 11/10/2020 | 7.68% | KeyBanc | →$350 | 開始承保 | →超重 |
| 10/14/2020 | -7.7% | 斯蒂芬斯公司 | →$300 | 開始承保 | →等重 |
| 04/24/2020 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 2019年12月12日 | - | B of A證券 | 評級下調 | 中性→表現不佳 | |
| 2019年07月26日 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 2019年05月01日 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 2019年04月23日 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 |
What is the target price for West Pharmaceutical Servs (WST)?
西部藥業Serv(WST)的目標價格是多少？
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Stephens & Co. on October 27, 2023. The analyst firm set a price target for $390.00 expecting WST to rise to within 12 months (a possible 19.99% upside). 13 analyst firms have reported ratings in the last year.
Stephens&Co.於2023年10月27日報道了West Pharmtics Serv(紐約證券交易所代碼：WST)的最新目標價。這家分析公司將目標價定為390.00美元，預計美國西部夏令時間將在12個月內上漲(可能上漲19.99%)。過去一年，有13家分析公司公佈了評級。
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
西部藥業Serv(WST)的最新分析師評級是多少？
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Stephens & Co., and West Pharmaceutical Servs maintained their overweight rating.
對West Pharmtics Serv(紐約證券交易所代碼：WST)的最新分析師評級是由Stephens&Co.提供的，West Pharmtics Serv維持其增持評級。
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
下一次分析師對西方製藥服務公司(WST)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on October 27, 2023 so you should expect the next rating to be made available sometime around October 27, 2024.
分析師在做了廣泛的研究後得出了股票評級，研究內容包括查閱公開財務報表、與西方製藥服務公司的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月做一次，所以你每年應該對每家公司進行4次評級。West Pharmaceutical Servs的最後一次評級於2023年10月27日提交，因此您應該期待下一次評級將在2024年10月27日左右提供。
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
分析師對西方製藥服務公司(WST)的評級正確嗎？
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $420.00 to $390.00. The current price West Pharmaceutical Servs (WST) is trading at is $325.02, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的西方製藥服務公司(WST)的評級保持不變，目標價在420.00美元至390.00美元之間。西方醫藥公司目前的交易價格為325.02美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。